Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of <scp>SURMOUNT</scp> ‐ <scp>CN</scp> trial
Tirzepatide was associated with significantly reduced predicted 10-year risk of T2D among SURMOUNT-CN participants with obesity or overweight, irrespective of baseline BMI and prediabetes status.
Authors
- Hanxi Zhang (ORCID: https://orcid.org/0000-0002-4981-6073)
- Feng Tao (ORCID: https://orcid.org/0000-0002-0623-6298)
- Zhifeng Cheng (ORCID: https://orcid.org/0000-0001-6019-399X)
- Min Zhang (ORCID: https://orcid.org/0000-0002-9694-8212)
- Yin Sun (ORCID: https://orcid.org/0009-0000-8793-3169)
- Yibing Lu (ORCID: https://orcid.org/0000-0002-0018-4714)
- Xiang Song (ORCID: https://orcid.org/0000-0002-1704-4339)
- Si Si
- Xiao Ma (ORCID: https://orcid.org/0000-0001-8835-2286)
- Hong Chen (ORCID: https://orcid.org/0000-0001-5528-3923)
- Ming Rong Liu (ORCID: https://orcid.org/0000-0003-2665-4072)
- Yang Yang (ORCID: https://orcid.org/0000-0003-4188-1230)
- Lin Zhao (ORCID: https://orcid.org/0000-0003-2994-2387)
Institutions
- Harbin Medical University (CN)
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Tianjin Medical University General Hospital (CN)
- Zhujiang Hospital (CN)
- Fourth Affiliated Hospital of Harbin Medical University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Shanghai Traditional Chinese Medicine Hospital (CN)
- Lilly (China) (CN)
- Southern Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1111/dom.16439
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company